News and Press Releases
Press releases
Theralase Releases 2019 Annual General Meeting Video Presentations
Press ReleaseToronto, Ontario – June 28, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo...
Regulatory Updates from Health Canada and US FDA
Press ReleaseToronto, Ontario – June 27, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDy...
Theralase Files Prospectus for Offering of Units
Press ReleaseNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario – June 26, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
Health Canada Approves Amended Clinical Trial Application
Press ReleaseToronto, Ontario – June 26, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
Press ReleaseResearch Detailing Advantages of Rutherrin® PhotoDynamic Therapy in deadly brain cancer, GlioBlastoma Multiforme (“GBM”) to be Published in the Journal of Neuro-Oncology Advances Toronto, Ontario – June 25, 2019, Theralase® Techn...
Theralase® Releases 2018 Year End Audited Financial Statements
Press ReleaseToronto, Ontario – April 17, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated ...
Theralase Releases Amended and Restated 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – June 18, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
Theralase Releases 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – May 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
Press ReleaseToronto, Ontario – May 20, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseToronto, Ontario – May 13, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
